Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.


The treatment of chronic myelogenous leukemia (CML) has been revolutionized by the development of the small-molecule tyrosine kinase inhibitor imatinib. The primary target for this drug is the oncogenic BCR-ABL kinase. Five-year survival rates for patients in chronic phase CML is now greater than 80%. Patients who have advanced beyond the chronic phase to… (More)
DOI: 10.1053/j.seminoncol.2007.12.002


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics